SCHEMBL4708247

SCHEMBL4708247

COc1ccc(COc2ccc3c(c2)CCC(C)C3=O)cc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP24A1 Q07973 5/20 0.56
CYP26A1 O43174 2/20 0.56
MAOA P21397 8/20 0.51
MAOB P27338 8/20 0.51
CYP19A1 P11511 1/20 0.50
ITGB3 P05106 1/20 0.50
ITGA2B P08514 1/20 0.50
CYP27A1 Q02318 2/20 0.47
GPR84 Q9NQS5 1/20 0.46
DRD2 P14416 1/20 0.45
HTR2A P28223 1/20 0.45
HTR2C P28335 1/20 0.45
HTR2B P41595 1/20 0.45
SIGMAR1 Q99720 1/20 0.45
STAT3 P40763 1/20 0.45
THRA P10827 1/20 0.45
THRB P10828 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4707087 0.87 ACHE (0.56) CYP24A1CYP26A1MAOAMAOBCYP19A1
SCHEMBL630841 0.85 ACHE (0.58) CYP24A1CYP26A1CYP19A1CYP27A1DRD2
SCHEMBL4708272 0.80 MAOB (0.67) MAOAMAOB
SCHEMBL3857144 0.78 MAOA (0.81) MAOAMAOB
SCHEMBL14286892 0.77 ACHE (0.55) CYP24A1CYP26A1CYP19A1CYP27A1DRD2
SCHEMBL5237018 0.74 ACHE (0.71) CYP24A1CYP26A1MAOBCYP19A1CYP27A1
SCHEMBL5237012 0.74 ACHE (0.71) CYP24A1CYP26A1MAOBCYP19A1CYP27A1
SCHEMBL5237022 0.74 ACHE (0.71) CYP24A1CYP26A1MAOBCYP19A1CYP27A1
SCHEMBL31748950 0.73 MAOB (0.61) CYP24A1MAOAMAOBITGB3ITGA2B
SCHEMBL227895 0.73 MAOB (0.61) CYP24A1MAOAMAOBITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2001844-A2 BICYCLIC CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS Amgen, Inc (US) 2008-12-17 EP disclosed
US-20070244155-A1 Bicyclic carboxylic acid derivatives useful for treating metabolic disorders AMGEN INC. (US) 2007-10-18 US disclosed
US-20070244155-A1 Bicyclic carboxylic acid derivatives useful for treating metabolic disorders AMGEN INC. (US) 2007-10-18 US disclosed
US-20070244155-A1 Bicyclic carboxylic acid derivatives useful for treating metabolic disorders AMGEN INC. (US) 2007-10-18 US disclosed
WO-2007106469-A2 BICYCLIC CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS AMGEN INC. (US) 2007-09-20 WO disclosed
WO-2007106469-A2 BICYCLIC CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS AMGEN INC. (US) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244155-A1 Bicyclic carboxylic acid derivatives useful for treating metabolic disorders GOT2, PC, GOT1 CYP24A1 250/4885CYP26A1 158/4885MAOA 737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.